On 18 April 2024, the US Food and Drug Administration (FDA) approved Roche’s Alecensa (alectinib), an oral anaplastic ...

Agricultural Activator Adjuvant Market set to hit worth US$ 6.6 billion at CAGR 4.9% during forecast period 2024 to 2034 ...

The global agricultural adjuvant market is forecast to expand at 6% CAGR over the forecast period, as per FMI’s analysis. The ...

Adjuvant pembrolizumab had an estimated 91.2% overall survival rate after 4 years compared with 86.0% for patients with clear ...

Adjuvant radiotherapy (RT) after radical prostatectomy did not improve outcomes in prostate cancer as compared with salvage ...

Roche has broken new ground with its ALK inhibitor Alecenesa, becoming the first drug in the class to be approved by the FDA ...

The Food and Drug Administration (FDA) has approved Alecensa (alectinib) for adjuvant treatment in adults following tumor resection of anaplastic lymphoma kinase (ALK)-positive non-small cell lung ...

The US Food and Drug Administration (FDA) has approved alectinib (Alecensa, Genentech) in the adjuvant setting following ...

Alectinib approved by US FDA for auxiliary treatment of patients with anaplastic lymphoma kinase (ALK)-positive non-small ...

Approval based on Phase III ALINA study showing Alecensa reduced the risk of disease recurrence or death by an unprecedented ...

The FDA has approved Alecensa (alectinib) as adjuvant treatment for adults with ALK-positive non-small cell lung cancer.